Dividend Assets Capital LLC Has $7.19 Million Stake in Zoetis Inc. (NYSE:ZTS)

Dividend Assets Capital LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 37.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 43,655 shares of the company's stock after buying an additional 11,834 shares during the period. Zoetis accounts for approximately 1.4% of Dividend Assets Capital LLC's investment portfolio, making the stock its 26th largest holding. Dividend Assets Capital LLC's holdings in Zoetis were worth $7,188,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after purchasing an additional 2,978 shares during the last quarter. Strategic Financial Concepts LLC acquired a new position in Zoetis in the fourth quarter valued at about $1,646,000. Kingsview Wealth Management LLC boosted its holdings in Zoetis by 1.0% during the fourth quarter. Kingsview Wealth Management LLC now owns 9,986 shares of the company's stock worth $1,627,000 after buying an additional 97 shares during the last quarter. Howland Capital Management LLC grew its position in shares of Zoetis by 15.1% during the 4th quarter. Howland Capital Management LLC now owns 2,594 shares of the company's stock worth $423,000 after buying an additional 341 shares during the period. Finally, Stephens Inc. AR increased its stake in shares of Zoetis by 22.1% in the 4th quarter. Stephens Inc. AR now owns 59,025 shares of the company's stock valued at $9,617,000 after acquiring an additional 10,681 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

ZTS has been the topic of a number of recent analyst reports. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Piper Sandler lifted their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $212.75.

Zoetis Stock Performance

NYSE:ZTS traded down $0.79 during mid-day trading on Wednesday, hitting $166.31. The stock had a trading volume of 2,473,138 shares, compared to its average volume of 2,547,541. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company's 50 day simple moving average is $157.58 and its 200 day simple moving average is $164.14. The stock has a market cap of $74.04 billion, a price-to-earnings ratio of 30.40, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.38 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is currently 35.91%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.